BiOptic Inc. and CatchGene Co., Ltd. Complete Production Capacity Integration

BiOptic Inc. (Stock Code: 6850) announced on the 12th that its subsidiary, OpenGene, has officially been merged into BiOptic Inc. The nucleic acid extraction instrument and reagent production lines previously located at the Zhonghe facility have been relocated to BiOptic’s second plant in Xindian. Going forward, the parent company will lead product development and production planning, while OpenGene will focus on market expansion to effectively integrate group resources.

With this consolidation, BiOptic Inc. will be able to offer a comprehensive one-stop solution for genetic testing. Additionally, the maximum production capacity is expected to increase by more than 50%, helping to meet the growing demand in the precision medicine testing market.

Chairman Tsai Shou-Guan noted that the internal integration of the group has been completed, including process management optimization, system integration, and enhanced team collaboration. These improvements have significantly streamlined production flows, reduced handling and communication costs, and created favorable conditions for deep integration between teams. This, in turn, will notably enhance operational efficiency, reduce hidden costs, and further expand profit margins.

Tsai emphasized that nucleic acid extraction is a crucial step for ensuring the quality of next-generation sequencing (NGS) samples. It is also a key process in various applications within the fields of biotechnology, medical diagnostics, reagent development, and validation. The group’s self-developed automated low-volume circulating nucleic acid purification instrument, iCATCHER, can extract ultra-trace amounts of ctDNA (circulating tumor DNA) from liquid samples. With advances in NGS technology, ctDNA is increasingly being used as an alternative to physical tumor biopsies, becoming a vital tool for cancer prediction, diagnosis, and monitoring. When combined with the company’s proprietary Qsep Ultra biofragment analyzer and related reagents, the integrated application enhances product competitiveness across precision medicine, predictive healthcare, cancer screening, and personalized medical services.

Recently, BiOptic Inc. reported February revenue of NT$14.3 million, marking a 41.87% year-over-year increase. The cumulative revenue for the first two months reached NT$32.89 million, up 26.48% from the previous year. This growth is mainly attributed to sustained order transfers from the European market and the success of revised distribution strategies in China, which significantly boosted sales of instruments and cartridges.

The company stated that following the completion of this integration phase, it will fully focus on expanding both domestic and international markets. BiOptic aims to broaden its business across three key areas—scientific research, genetic testing, and clinical diagnostics—while accelerating its transformation and upgrade. With the synergy from the group integration becoming increasingly evident, the company remains optimistic about its operational performance for the full year.